Drug Trial Radar · NCT05021835
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,385
Actual
Start
Aug 30, 2021
Primary completion
Jun 9, 2026
Study completion Jun 9, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Aug 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine doctors cannot prescribe. Participants will get the study medicine in a pre filled syringe. Participants will need to use the pre filled syringe to inject the study medicine into a skinfold once-monthly. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have blood and urine samples taken at most of the clinic visits. Participants will have their heart examined using sound waves (echocardiography) and electrodes (electrocardiogram). Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
Conditions
- Cardiovascular Risk
- Chronic Kidney Disease
- Inflammation
Interventions
Ziltivekimab BDrug
Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
Ziltivekimab CDrug
Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
Placebo (Ziltivekimab B)Drug
Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
Placebo (Ziltivekimab C)Drug
Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first occurrence of 3-point Major Adverse Cardiovascular Event (MACE), a composite endpoint consisting of: Cardiovascular (CV) death, non-fatal Myocardial Infarction (MI) and non-fatal strokeTime frame: From randomisation (month 0) to end-of-study (up to 48 months)
Locations
1,073 sites in 38 countries. Site status is shown where the registry gives one.
Uni of Alabama at Birmingham
Birmingham, Alabama
Chambliss Clinical Trials LLC
Montgomery, Alabama
Lenzmeier Fam Med CCT Research
Glendale, Arizona
Aventiv Research Inc.
Mesa, Arizona
Univ of Arkansas Med Sciences
Little Rock, Arkansas
Unity Health-Searcy Medical Center
Searcy, Arkansas
National Heart Institute Cal
Beverly Hills, California
California Inst Of Renal Res
Chula Vista, California
California Institute of Renal Research #10
Chula Vista, California
Valley Clinical Trials
Covina, California
Valiance Clinical Research
Huntington Park, California
Scripps Wht Diab Inst La Jolla
La Jolla, California
Balboa Nephro Med Gr Inc LaMes
La Mesa, California
First Valley Medical Group
Lancaster, California
VA Loma Linda Hlthcr Sys
Loma Linda, California
Pacific Clinical Studies
Los Alamitos, California
Angel City Research, Inc.
Los Angeles, California
North America Research Institute
Lynwood, California
Hoag Medical Group
Newport Beach, California
Valley Clinical Trials, Inc.
Northridge, California
Desert Oasis Hlthcr Med Group
Palm Springs, California
Riverside Nephrology Physicians
Riverside, California
N America Res Inst - San Dimas
San Dimas, California
Lundquist Inst-Biomed Innovtn
Torrance, California
Denver Health Outpatient Medical Center
Denver, Colorado
Bridgeport Hospital
Bridgeport, Connecticut
VA-Connecticut (VACHS)
West Haven, Connecticut
George Washington Uni Med
Washington D.C., District of Columbia
Excel Med Ctr Clinical Trials
Boca Raton, Florida
Florida Premier Cardiology
Boynton Beach, Florida
Innovative Research of W FL
Clearwater, Florida
Northeast Research Institute
Fleming Island, Florida
Integrative Research Assoc Inc
Fort Lauderdale, Florida
Elixia Pines
Hollywood, Florida
Encore Medical Research LLC
Hollywood, Florida
Northeast Research Institute
Jacksonville, Florida
Est Cst Inst for Rsrch,Jksnvil
Jacksonville, Florida
Baptist Heart Specialists
Jacksonville, Florida
Clinical Research of Cent FL
Lakeland, Florida
Pharmax Research Clinic
Miami, Florida
Showing 40 of 1,073 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.